Skip to main content

BTIG Sticks to Their Hold Rating for Hologic (HOLX)

Tipranks - Tipranks - Wed Jan 28, 7:44AM CST

In a report released yesterday, Ryan Zimmerman from BTIG reiterated a Hold rating on Hologic. The company’s shares closed yesterday at $75.19.

Claim 50% Off TipRanks Premium

Zimmerman covers the Healthcare sector, focusing on stocks such as Solventum Corporation, Organogenesis Holdings, and GE Healthcare Technologies Inc. According to TipRanks, Zimmerman has an average return of -0.2% and a 43.32% success rate on recommended stocks.

Hologic has an analyst consensus of Hold, with a price target consensus of $77.00, a 2.41% upside from current levels. In a report released today, TipRanks – xAI also downgraded the stock to a Hold with a $80.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Hologic’s latest earnings release for the quarter ending June 28, the company reported a quarterly revenue of $1.02 billion and a net profit of $194.9 million. In comparison, last year the company earned a revenue of $1.01 billion and had a net profit of $194.5 million

Read More on HOLX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).